

What: Executive Committee Agenda
When: October 12, 2023; 2:30-3:30 pm PT
Where: ZOOM

<https://us02web.zoom.us/j/88488833279?pwd=Qmp1Qys4NEZLSnBGeEx5dC8ySEg1QT09>

+1 669 900 9128 US (San Jose) or +1 253 215 8782 US (Tacoma)
Meeting ID: 884 8883 3279 and Passcode: 716983

Notice: The meeting may be recorded for the benefit of the minute-taker. The WVA intends to delete the recording after the minutes are approved.

AGENDA

Approx. Time	*	Page	Topic/[Anticipated Action]	Presented by:
2:30-2:35 pm			1. Welcome & Introductions a) Notice of Meeting Recording	J. Zell / J. Dunn
2:35-2:40 pm	*	Pgs. 3-4	2. Calendar Consent Items a) Approve August 17, 2023 Meeting Minutes	J. Dunn
2:40-3:10 pm	*	Pgs. 5-13	3. Financial Updates a) Current Financial Position b) Reserves Threshold Modeling c) Future Assessments/In-patient d) Direct Care Practices	P. Miller / J. Zell
3:10-3:25 pm	*	Pgs. 14-18	4. Legislative Update a) Coalition Building b) Lobbyist Proposal i. Vote to Approve Lobbying Engagement	J. Zell
3:30 pm			5. Closing	J. Dunn

*Indicates agenda item attached

**Washington Vaccine Association
Executive Committee Meeting**

August 17, 2023; 2:30-3:30 p.m. PT

- I. Attendance.** This meeting was conducted solely by webinar. Participating in all or part of the meeting were the following individuals:

Directors:

John Dunn, MD, Kaiser Permanente, Chair
Beth Harvey, MD, South Sound Pediatrics, Vice Chair
Ed Marcuse, MD, Emeritus Professor of Pediatrics, Secretary
John Soback, MD, Regence, Treasurer

Helms & Company, Inc.:

Patrick Miller, MPH, WVA Administrative Director
Ashley Ithal, MPH, WVA Program Support

Others:

Eric Sonju, WA Attorney General Office
Michelle Roberts, Washington Department of Health
Jamalia Sherls-Jones, Washington Department of Health
Meghan Cichy, Washington Department of Health
Kiran Griffith, Esq., Stoel, Outside Counsel
Anne Redman, Esq., Perkins Coie, Outside Counsel

WVA:

Julia Walter Zell, MA., Esq., Executive Director

II. Summary of Actions Taken and/or Recommended

Actions Taken (votes adopted)

- i. To approve June 8, 2023 meeting minutes.

III. Minutes

Welcome & Introduction

Ms. Zell called the meeting to order at 2:33 p.m. and provided the notice of recording.

Calendar Consent Items

After hearing no comments, Ms. Zell asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously

VOTED: To approve June 8, 2023 meeting minutes.

Current Financial Position

Mr. Miller provided a summary of the unaudited financials through June 30, 2023. Mr. Miller noted that the WVA is in the middle of the FY23 financial audit. Final financial figures for FY23 will be delivered to the WVA Finance Committee in September 2023 for approval. In terms of current cash position, Mr. Miller reported that the WVA continues to burn down cash as anticipated, and that there will be an impact from the COVID-19 commercialization this fall. The FY23 administrative budget ended with an excess of approximately \$235,000 due to unused provider education and mailings, website support, and unused provider services. Mr. Miller reported that July 2023 unaudited financials and the July ED AD report will be distributed next week.

FY2023 Audit

Ms. Zell provided an update on the ongoing audit being conducted by CliftonLarsonAllen, LLP. The FY2023 audit will be completed in September.

COVID-19 Update

Ms. Zell reported that the development of the communication plan is complete with drafts of communications ready for distribution as soon as final pricing and coding is known. Mr. Miller reported that Moderna information was delivered this week.

44 Assessment Grid Adherence
45 Mr. Miller reported that the WVA team has conducted several analyses to review DBAs with service dates from
46 July 2023 forward to account for the effective date of the WVA Vaccine Assessment Grid changes. The WVA
47 team has communicated with its largest payers to address any questions or issues. Overall, Mr. Miller reported
48 that most issues have been resolved and that the grid adherence process for July 2023 has gone well.
49

50 **IV. Executive Session**

51
52 On file with counsel.

53
54 **V. Closing**

55
56 The meeting concluded at 3:42 p.m.

Reestablishing Reserve Thresholds

Executive Committee

October 12, 2023

Discussion Overview


- ✓ Reserves Have Historically Been Three Months of Vaccines + Influenza
- ✓ Reserve Goal Set in April 2023 = \$30-32M end of FY2025/26
- ✓ September 2023 → COVID-19 Vaccines Were Added to Vaccine Grid
- ✓ October 2023 → Board Approved \$14.3M of Reserves for Nirsevimab
- ❑ Reserve of 3 Months Supply (\$36M) + Influenza (\$4.5M) + (\$5M contingency) = \$45.5M by End of FY2025(?)/26(?)/27(?)

Today's Discussion

Reserve Threshold Considerations


- Consideration of 1, 2, or 3 Years to Rebuild the Reserves
- Lower Expected Bond Portfolio Returns Due to Smaller Portfolio
- Need Additional Reserves for New Vaccines
- Escalating Vaccine Inflation
- WA DOH's COVID-19 Estimates of \$12M/Year
- WA DOH's RSV Nirsevimab Estimates of \$10.2M-20.4M/Year
- Grid Must Remain Below the Private Market Prices

CDC Prices of Recent ACIP Additions



Doses and Costs – Summary

% of Projected Doses and % of Projected Costs* SFY 2024



*Excludes Indirect and Cost Recovery Fees

RSV Projections – Source: WA DOH (09/14/23)

Fund Type Categories	If uptake is 100% of eligible population - number of doses annually	If uptake is 100% of eligible population - cost annually	Assume 70% uptake - number of doses annually	Assume 70% uptake - cost annually	Assume 50% uptake - number of doses annually	Assume 50% uptake - cost annually
Total Estimated: total 0 population plus 2 additional doses for 8-19-month-olds who are immunosuppressed and/or AI/AN.	109,793	\$43,368,108	76,855	\$30,357,676	54,896	\$21,684,054
Breakdown by Fund Source						
VFC (50%)	54,896	\$21,684,054	38,427	\$15,178,838	27,448	\$10,842,027
WVA (47%)	51,603	\$20,383,011	36,122	\$14,268,108**	25,801	\$10,191,505
CHP/CHIP (3%)	3,294	\$1,301,043	2,306	\$910,730	1,647	\$650,522
Total Estimate Cost Annually	109,793	\$43,368,108	76,855	\$30,357,676	54,896	\$21,684,054

**Assumes \$395/dose from CDC Price List. Private Market would be \$495/dose or \$17,880,287.

Rebuilding Reserves – Board Directed Options

- Reserve of 3 Months Supply (\$36M) + Influenza (\$4.5M) + (\$5M contingency) = \$45.5M
- Assumes \$14.3M RSV Supply Paid for with Reserves
- Annual Increases Versus Flat Assessment Grid

	FY2023	FY2024	FY2025	FY2026
<u>OPTION 1:</u> Cash Reserves Ending Balance – FY25 ↑<u>30%</u> ; FY26 ↑<u>20%</u>	\$43.6M	\$19.5M	\$40.8	\$47.3M
<u>OPTION 2:</u> Cash Reserves Ending Balance – FY25 ↑<u>25%</u> ; FY26 ↑<u>30%</u>	\$43.6M	\$19.5M	\$35.7M	\$47.2M
<u>OPTION 3:</u> Cash Reserves Ending Balance – FY25 ↑<u>20%</u> ; FY26 ↑<u>40%</u>	\$43.6M	\$19.5M	\$30.6M	\$46.2M

Funding Request Approved by BOD 09.28.2023

Budget Item	FY2024 Projected Amount
Legal - Contracting; Counsel; Meetings; Interpretation; Consultation	\$75,000
Government Relations - Federal and State; Coordination with Parties; Lobbying	\$35,000
Finance/Audit - Segmentation of Accounts; Settlement Reporting; Collections; Increased Audit Breadth	\$50,000
Operations/Compliance/IT - Compliance Program Expansion; Recovery Management; Settlement Reporting; Systems Set Up	\$55,000
Communications - Graphic Designer; Printing; Postage; Mailing Services; Email Services	\$35,000
Total	\$250,000

Timeline – Next Grid Approval

Other Milestones:

- Nov 2023 – New DOH Projections
- Apr 2024 – Final DOH Projections

